profit from every $100 of sales.
$0$100
Belite Bio
$169.96+8.99% today
+41.0% in 1 year
1-year low $109.181-year high $193.61
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Belite Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$77.6 million of profit last year.
SalesProfit
Belite Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Belite Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Belite Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -13 | -32 | -40 | -84 | |
| -12 | -31 | -36 | -77 | |
| -13 | -32 | -36 | -78 | |
| -0.63 | -1.19 | -1.18 | -2.31 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 44 | 95 | 152 | 781 |
| Cash | 42 | 88 | 32 | 353 |
| Total debt | 1 | 1 | 1 | 0 |
| Total liabilities | 3 | 4 | 6 | 10 |
| 42 | 90 | 146 | 770 | |
| 20 | 27 | 31 | 34 | |
| -23.6% | -27.3% | -19.5% | -8.0% | |
| -30.5% | -35.0% | -24.8% | -10.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11 | -30 | -29 | -37 | |
| 0 | 0 | 0 | 0 | |
| -12 | -30 | -29 | -37 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 4 | 9 | 39 |
Valuation
- –
- –
- –
- 6.2×
- –
- –
- –
- -0.5%
- -1.1%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -10.9%
- -31.4%
- -23.0%
- -9.9%
- -10.9%
- –
Growth
- –
- –
- −26.5%
- –
- +8.6%
Financial health
- 4.2×
- 0.00
- 0.1%
- –
- 50.02
- 50.02
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 952
Bottom 20%of 883
Bottom 36%of 985
What analysts expect
- Average price target
- $203.00
- Range
- $187.00 – $223.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 2, 2026 | -0.38 | -0.56 | +32.1% |
| Nov 10, 2025 | -0.65 | -0.53 | −22.6% |
| Aug 11, 2025 | -0.50 | -0.47 | −6.4% |
| May 13, 2025 | -0.45 | -0.36 | −25.0% |
| Mar 17, 2025 | -0.32 | -0.30 | −6.7% |
| Nov 12, 2024 | -0.28 | -0.30 | +6.7% |
| Aug 9, 2024 | -0.31 | -0.28 | −10.7% |
| May 13, 2024 | -0.27 | -0.34 | +20.6% |
News
Belite Bio Non-GAAP EPS of -$0.60 beats by $0.17Seeking Alpha · Nov 12, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
10No pass
Benjamin Graham
25No pass
Philip Fisher
24No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
12No pass
Terry Smith
4No pass
Questions about Belite Bio
Is Belite Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Belite Bio AI analysis
What does Belite Bio do?
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. It is in Biotechnology, based in San Diego, CA, United States, with 41 employees.
Does Belite Bio pay a dividend?
No. Belite Bio does not pay a dividend at the moment.
Is Belite Bio stock halal?
Yes. Belite Bio passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Belite Bio stock done over the past year?
Up 41.0% over the past twelve months, to $169.96. It traded between $109.18 and $193.61 and is 12.2% below its high.
Who are Belite Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Belite Bio's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.